Method Profile
Compare tumor viability and vascular-network responses after adding fibroblasts and endothelial cells to patient-derived synovial sarcoma organoids.
Study stromal–vascular contributions to chemotherapy and antiangiogenic drug activity.
Patient-derived synovial sarcoma organoids and cancer-associated fibroblasts combined with human umbilical vein endothelial cells.
Matched conventional organoids and perfused vascularized chips, with parallel tumor-viability and vascular-network measurements.
Tumor models
Synovial sarcoma organoid lines established within a 24-line collection.
Microenvironment
Patient-derived cancer-associated fibroblasts and laboratory-source HUVECs.
Drugs
Doxorubicin alone or with ifosfamide or anlotinib; additional pazopanib and vorinostat comparisons.
Compare matched patient-derived cultures across formats, then relate tumor response to vascular disruption and the relevant molecular measurements.
Paired tumor-only and stromal–vascular drug testing.
Three paired models in the doxorubicin IC50 table; one representative clinical comparison.
Conventional organoids versus the vascularized chip, with single-agent and combination conditions.
The chip was less sensitive to doxorubicin; anlotinib increased sensitivity in a subset and disrupted vascular networks.
A patient-derived synovial sarcoma collection was extended into a vascularized chip. Paired drug tests showed lower chemotherapy sensitivity in the more complex model and variable responses to adding anlotinib.
